Key Developments: Oculus Innovative Sciences Inc (OCLS.O)

OCLS.O on Consolidated Issue listed on NASDAQ Capital Market

1.57USD
19 Dec 2014
Price Change (% chg)

$0.10 (+6.80%)
Prev Close
$1.47
Open
$1.45
Day's High
$1.61
Day's Low
$1.45
Volume
78,059
Avg. Vol
74,050
52-wk High
$5.99
52-wk Low
$1.33

Search Stocks

Latest Key Developments (Source: Significant Developments)

Oculus Innovative Sciences receives european CE Mark for New Microcyn based Atopic Dermatitis Hydrogel
Thursday, 30 Oct 2014 08:12am EDT 

Oculus Innovative Sciences Inc:Says issuance of a new CE Mark in Europe for Microcyn-based Pediacyn Hydrogel.Clinical results of the study includes statistically significant 50 pct reduction in the body surface area of the atopic dermatitis from baseline to week 4.Symptoms of the disease as assessed by the investigators showed that the majority of the patients at week 4 were clear or almost clear of the disease.Severity of the symptoms as indicated by the patients showed an 81 pct reduction by week 4 from the baseline.  Full Article

Oculus Innovative Sciences Inc gives Q1 2015 guidance below analysts' estimates - Conference Call
Thursday, 12 Jun 2014 04:30pm EDT 

Oculus Innovative Sciences Inc:Expects Q1 2015 total revenue to be in the range of $3.1 million.Expects Q1 2015 EBITDA to be in the range of $1.2 million negative.Q1 2015 revenue of $3.6 million and EBITDA of $(0.78) million - Thomson Reuters I/B/E/S.  Full Article

Oculus Innovative Sciences Inc receives approval for oral and throat infection products in Mexico
Wednesday, 19 Feb 2014 08:08am EST 

Oculus Innovative Sciences Inc:Says regulatory approval in Mexico for the company's new Microcyn60 Oral Care family of products intended for use as an adjunct treatment in both mouth and throat infections.  Full Article

Oculus Innovative Sciences Inc Receives CE Mark for use of Microcyn
Tuesday, 4 Feb 2014 08:08am EST 

Oculus Innovative Sciences Inc:Receives the European CE Mark for the Microcyn -based GramaDerm Solution and GramaDerm Hydrogel.Both products are intended for use in the topical treatment of mild to moderate acne and are designed to complement other acne treatments.  Full Article

Oculus Innovative Sciences Inc announces $2.2 mln securities offering
Wednesday, 4 Dec 2013 11:00pm EST 

Oculus Innovative Sciences Inc:Says an offering to sell securities to select accredited investors for aggregate gross proceeds of $2.2 mln.Says it intends to use the net proceeds from the offering for working capital and general corporate purposes.Says the securities in the offering include 550,000 shares of Oculus common stock at a price of $4.00 per share with no warrant coverage.Says the offering is expected to close on or about Dec. 9.Says Dawson James Securities, Inc. acted as the exclusive placement agent for the offering.  Full Article

Oculus Innovative Sciences Inc Receives FDA Clearance for Microcyn Scar Management HydroGel
Wednesday, 4 Dec 2013 08:08am EST 

Oculus Innovative Sciences Inc:Says that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Microcyn Scar Management HydroGel.Says The Rx product, under the supervision of a healthcare professional, is intended for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds.Says Oculus U.S. dermatology partner, Quinnova Pharmaceuticals, intends to commercialize the product in the first half of 2014.  Full Article

Oculus Innovative Sciences Inc Announces Confidential Submission Of Draft Registration Statement For Initial Public Offering To Securities and Exchange Commission By Subsidiary Ruthigen, Inc.
Tuesday, 28 May 2013 08:08am EDT 

Oculus Innovative Sciences Inc announced that Ruthigen, Inc., a wholly owned subsidiary of the company, submitted a draft registration statement on a confidential basis to the U.S. Securities and Exchange Commission for a possible initial public offering of Ruthigen common stock. The number of shares to be offered and the price range for the offering have not yet been determined.  Full Article

Oculus Innovative Sciences Inc Announces Closing of Public Offering of 8,625,000 Shares of Common Stock
Tuesday, 12 Mar 2013 09:01pm EDT 

Oculus Innovative Sciences Inc announced the closing of its underwritten public offering of 8,625,000 shares of common stock at an offering price of $0.40 per share, including 1,125,000 shares of its common stock to cover the over-allotment. Oculus received gross proceeds of $3.45 million. Oculus intends to use the net proceeds from this offering for the repayment of debt and for general corporate purposes. In connection with the repayment of debt, Oculus intends to retire a portion of the common stock previously issued to its lenders. Aegis Capital Corp. acted as the sole book-running manager for the offering. Dawson James Securities, Inc. acted as a co-manager for the offering.  Full Article

Oculus Innovative Sciences Inc Announces Full Exercise Of Underwriters' Over-Allotment Option
Thursday, 7 Mar 2013 05:20pm EST 

Oculus Innovative Sciences Inc announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 1,125,000 shares of common stock, at a public offering price of $0.40 per share in connection with its previously announced underwritten public offering of 7,500,000 shares of common stock, bringing total gross proceeds from the offering to approximately $3.5 million. Aegis Capital Corp. is acting as the sole book-running manager for this offering. Dawson James Securities, Inc. is acting as a co-manager for the offering.  Full Article

Oculus Innovative Sciences Inc Announces Proposed Public Offering Of Common Stock
Wednesday, 6 Mar 2013 04:01pm EST 

Oculus Innovative Sciences Inc announced that it intends to offer for sale its common stock in an underwritten public offering. Oculus intends to use the net proceeds from this offering for the repayment of debt and for general corporate purposes. In connection with the repayment of debt, the Company intends to retire a portion of the common stock previously issued to its lenders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aegis Capital Corp. is acting as the sole book-running manager for the offering.  Full Article

Search Stocks